GERN
Geron Corporation · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 335 | $412 | n/a | n/a |
| Q2 2026 | 91 | +1 | 281.46M | $360.40M | +7 | −6 |
| Q1 2026 | 93 | -3 | 271.64M | $404.62M | +7 | −10 |
| Q4 2025 | 95 | -3 | 246.07M | $324.82M | n/a | −3 |
| Q3 2025 | 17 | 0 | 193.54M | $265.15M | +2 | −2 |
| Q2 2025 | 14 | +1 | 162.89M | $229.67M | +1 | n/a |
| Q1 2025 | 10 | -1 | 76.28M | $121.30M | n/a | −1 |
| Q4 2024 | 11 | +1 | 96.17M | $340.44M | +2 | −1 |
| Q3 2024 | 9 | 0 | 71.98M | $326.79M | +2 | −2 |
| Q2 2024 | 9 | n/a | 67.08M | $284.41M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assetmark, Inc | 335 | 0.0% | $412 | 0.0% | Held | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 253 holders, 492.17M shares, $730.64M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.